BIOexpress
Biotronik, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
On 2026-10-16, FDA recorded an approval decision for PMA supplement P050023/S209, submitted by Biotronik, Inc. under the Normal 180 Day Track. The supplement is associated with BIOexpress, described in the source as a dedicated interrogation-only device for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs).
The recorded supplement reason is a change in design, components, specifications or material. That reason describes the scope of the supplement rather than a new approval of the underlying system, and the source does not identify which component or specification changed. The device category is listed as DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER, with product code MRM and Cardiovascular specialty. The source provides no documents, so the specific modification, supporting data and any labeling effect remain unknown.
Readers should not infer clinical performance, compatibility or current labeling from this record; those details would require the underlying FDA documents, which are not included here.
FDA approval order statement
BIOexpress, a dedicated interrogation-only device for status checks of BIOTRONIK implantable pulse generators (IPGs, CRT-Ps), implantable cardioverter defibrillators (ICDs, CRT-Ds) and implantable cardiac monitors (ICMs)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 16, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P050023/S209
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P050023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P050023 · Original PMA
TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD
P050023/S209 received
Application receipt date recorded by FDA.
P050023/S211 · Related supplement
PSW 2601.U, NEO 2601.U, Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, R
P050023/S204 · Related supplement
Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I
P050023/S214 · Related supplement
Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, Rivacor Sky HF-T QP, Riva
P050023/S213 · Related supplement
Acticor Sky HF-T 481986; Rivacor Sky HF-T 481991; Rivacor Rise HF-T 482017; Rivacor Aura HF-T 482013; Acticor Sky HF-T Q
P050023/S215 · Related supplement
Ilivia 7 VR-T DX DF-1 ProMRI Ilivia 7 VR-T DF-1 ProMRI Ilivia 7 VR-T DF4 ProMRI Intica 7 VR-T DX DF-1 ProMRI Intica 7 VR
P050023/S209 · FDA decision
Normal 180 Day Track
P050023/S216 · Related supplement
Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT
Timeline entries are records held by MedtechLedger for P050023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P050023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Aug 10, 2006 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P050023/S209
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




